(Epi)genetic risk markers, predictors and mechanisms of psychotherapy in acrophobia

Not Applicable

• Conditions: F40.2; Specific (isolated) phobias

• Registration Number: DRKS00033150
• Lead Sponsor: niversitätsklinikum Freiburg - Klinik für Psychiatrie und Psychotherapie

Brief Summary

Not available

Detailed Description

Not available

Study Timeline

• Study Start: 2023-12-12
• Last Update Posted: 19 August 2024

Recruitment & Eligibility

• Status: Pending
• Sex: All
• Target Recruitment: 300

Inclusion Criteria

Caucasian descent (up to the third generation)
Proficient in spoken and written German

Exclusion Criteria

Current comorbid mental disorders apart from other specific phobias, suicidality (BDI-II item 9>0), severe neurological and/or somatic disorders, illegal drug use (assessed by urine toxicology), pregnancy, impaired 3D sight (as assessed using a stereo depth perception test), general medical contraindications, intake of psychoactive medication, or concomitant psychotherapy. Lifestyle-related habits (smoking, alcohol consumption, caffeine intake, physical activity, diet, BMI) will be recorded; excessive alcohol (more than 14 glasses/week), cigarette (more than 20 cigarettes/day) and caffeine (more than 4 cups/day) consumption will lead to study exclusion.

Study & Design

• Study Type: interventional
• Study Design: Not specified

Primary Outcome Measures

Name	Time	Method
Acrophobia symptoms measured using the Attitudes Towards Heights Questionnaire (ATHQ) and Acrophobia Questionnaire (AQ) before and after the intervention (at T0 and T1 - before and after six weeks after baseline).